NASA Twin ESCAPADE Probes Complete First Powered Earth Flybys Toward Mars as FDA Convenes Transcranial Ultrasound Roundtable
NASA reported that its twin ESCAPADE spacecraft completed the agency's first-ever powered Earth flybys at altitudes of 1,000 and 650 miles after a year in an L2 loiter orbit, setting course for Mars arrival in September 2027, while the US FDA and the Focused Ultrasound Foundation hosted a November 10 workshop on transcranial ultrasound for neurological and psychiatric therapies.
By 全球伯乐 News
Research and compilation
On this page
Breaking the Two-Year Mars Launch Window: Twin ESCAPADE Probes Execute Powered Earth Slingshots at 1,000 and 650 Miles
NASA’s Science Mission Directorate announced that the agency’s twin ESCAPADE (Escape and Plasma Acceleration and Dynamics Explorers) spacecraft have each completed a powered Earth flyby, combining Earth’s gravity with an approximately 9-minute trans-Mars injection engine burn to slingshot toward the Red Planet for scheduled 11-minute Mars orbit insertion burns on September 7 and September 9, 2027.1 The first spacecraft executed its close approach and engine firing at 5:00 a.m. EST on November 7 at an altitude of roughly 1,000 miles above Earth, followed by its twin two days later at 6:00 a.m. EST on November 9 at an altitude of about 650 miles—marking the first time NASA has used a powered Earth gravity assist to propel a spacecraft toward Mars.1

AI-generated editorial illustration: a matte terracotta sphere with two brass miniature spacecraft models on a dark basalt slab beside a frosted-glass acoustic focusing dome and metal probe represent interplanetary gravity-assist maneuvers and transcranial ultrasound evaluation, not flight hardware or clinical devices.
Led by the University of California, Berkeley’s Space Sciences Laboratory (SSL) alongside Rocket Lab, Blue Origin, Embry-Riddle Aeronautical University, and Advanced Space under NASA’s low-cost SIMPLEx program, ESCAPADE validated a new interplanetary staging architecture.1 Launched from Cape Canaveral on November 13, 2025, when Earth and Mars were on opposite sides of the Sun, the twin probes spent a year in a kidney-bean-shaped 'loiter' orbit around Earth-Sun Lagrange point 2 (L2) roughly one million miles away, collecting magnetotail observations before returning to Earth once planetary alignment arrived.1 Lead mission designer Jeff Parker and principal investigator Rob Lillis noted that this loiter-and-slingshot strategy decouples Mars launches from rigid 26-month alignment windows; beginning in June 2028, the two orbiters will fly in coordinated formations around Mars to measure simultaneously from two locations how the solar wind drives Martian atmospheric loss.1
Non-Invasive Blood-Brain Barrier Opening and Neuromodulation: FDA Hosts November 10 Transcranial Ultrasound Workshop
Alongside NASA’s orbital mechanics milestone, US biomedical regulators convened on November 10, 2026 (9:00 a.m. to 5:00 p.m. ET), for a full-day hybrid public workshop in McLean, Virginia, co-sponsored by the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) and the Focused Ultrasound Foundation, titled 'Research Roundtable on the Development of Transcranial Ultrasound for Neurological and Psychiatric Applications'.2
According to the FDA workshop charter, transcranial ultrasound is advancing rapidly across non-invasive neuromodulation and transient blood-brain barrier (BBB) opening to facilitate targeted drug delivery, brain liquid biopsy, and neuro-oncology therapies.2 While not issuing new binding device clearances by itself, the November 10 roundtable convened clinical and acoustic engineering specialists to establish shared technical benchmarks on patient safety risks, nonclinical bench and animal testing, clinical trial design and outcome endpoints for both therapeutic and diagnostic transcranial ultrasound devices, and specific evaluation safeguards for pediatric patients.2
Source notes
-
2026-11-09 · NASA's ESCAPADE Completes Powered Earth Flybys, Now En Route to Mars · NASA Science Mission Directorate. ↩ ↩2 ↩3 ↩4 ↩5
-
2026-11-10 · FDA and the Focused Ultrasound Foundation Co-sponsored Public Workshop: Research Roundtable on the Development of Transcranial Ultrasound for Neurological and Psychiatric Applications - 11/10/2026 · U.S. Food and Drug Administration (FDA). ↩ ↩2 ↩3


